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Alzheimer’s disease (AD) is the most common form of dementia, characterized
by a complex etiology that makes therapeutic strategies still not effective. A true
understanding of key pathological mechanisms and new biomarkers are needed, to
identify alternative disease-modifying therapies counteracting the disease progression.
Iron is an essential element for brain metabolism and its imbalance is implicated in
neurodegeneration, due to its potential neurotoxic effect. However, the role of iron in
different stages of dementia is not clearly established. This study aimed to investigate
the potential impact of iron both in cerebrospinal fluid (CSF) and in serum to improve
early diagnosis and the related therapeutic possibility. In addition to standard clinical
method to detect iron in serum, a precise quantification of total iron in CSFwas performed
using graphite-furnace atomic absorption spectrometry in patients affected by AD,
mild cognitive impairment, frontotemporal dementia, and non-demented neurological
controls. The application of machine learning techniques, such as clustering analysis
and multiclassification algorithms, showed a new potential stratification of patients
exploiting iron-related data. The results support the involvement of iron dysregulation
and its potential interaction with biomarkers (Tau protein and Amyloid-beta) in the
pathophysiology and progression of dementia.
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INTRODUCTION
Alzheimer’s disease (AD) is the most common cause of dementia (International, 2019),
characterized by a complex etiology and unsatisfactory therapeutic approaches (Long and
Holtzman, 2019). The duration of the preclinical and prodromal phase of AD varies from 10 to 20
years before clinical symptoms emerge (Vermunt et al., 2019). Mild Cognitive Impairment (MCI),
which identifies a clinical condition that includes impairment in memory and/or non-memory
cognitive domains, is assumed as a prodromal stage of AD, also referred to as MCI due to AD
(Albert et al., 2011).
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The presence of extracellular amyloid-beta (Aβ) deposition
as neuritic plaques and of intracellular accumulation of
hyperphosphorylated tau (p-Tau) as neurofibrillary tangles are
the two hallmark lesions that histopathologically characterize
the brains of AD patients (Ittner and Götz, 2011). However,
there is evidence that significant accumulation of these
pathological features can occur in non-demented individuals
(Fagan et al., 2007; Aizenstein et al., 2008; Villemagne et al.,
2008; Price et al., 2009) and also a high neuropathological
heterogeneity is observed in patients with clinical diagnosis
of AD (Rabinovici et al., 2016; Di Fede et al., 2018;
Robinson et al., 2018). The abnormal concentration in the
Cerebrospinal Fluid (CSF) of the proteins responsible for the
plaque formation, i.e., Aβ42, p-Tau, and total-Tau (t-Tau), is
assumed to be a measurable fingerprint of their brain deposition,
reflecting neurochemical changes arising from AD pathology
(Henry et al., 2013).
Although diagnostic criteria for AD and MCI are currently
used (Dubois et al., 2007, 2010; Albert et al., 2011; McKhann
et al., 2011; Sperling et al., 2011), defining the preclinical
state of MCI/AD aiming at discovering therapies preventing
the irreversible progression of AD (Fiandaca et al., 2014)
remains a challenge.
New biomarkers and a deeper comprehension of the
neuropathological processes involved in AD are urgently needed,
with the aim to identify alternative disease-modifying therapies
counteracting the disease progression. Actually, additional fluid
biomarkers measured in CSF or in blood (Palmqvist et al., 2020)
unraveled promising candidates, reflecting several inter-related
mechanisms of AD pathophysiology (Molinuevo et al., 2018).
In this regard, a growing amount of evidence suggests the
involvement of brain iron metabolism in the onset of several
neurodegenerative diseases, in particular its accumulation
in brain regions (Hare et al., 2013; Ward et al., 2014) and
its potential key role in the pathogenesis of AD (Silvestri
and Camaschella, 2008; Kozlov et al., 2017). Iron is an
essential element for our body but, in spite of its ubiquity,
it requires very careful managing (Gozzelino and Arosio,
2016). Free iron is a potentially toxic element that may
generate Reactive Oxygen Species (ROS) triggering oxidative
stress, lipid peroxidation, and DNA damage, also promoting
cell death in the novel form of “ferroptosis”(Dixon et al.,
2012; Hao et al., 2018). Therefore, most of the circulating
and stored iron is linked to proteins and other transporters,
such as transferrin (s-Tf) and ferritin (Pantopoulos et al.,
2012; Eid et al., 2017). The systemic organs and the brain
share the same iron regulatory mechanisms and pathways
based on iron-modulating proteins, providing a link to
the maintenance of iron homeostasis within the brain
(Singh et al., 2014).
The imbalance in iron homeostasis in AD and its interaction
with the more consolidated biomarkers Aβ and Tau have
been described (Ndayisaba et al., 2019; Spotorno et al., 2020),
supporting the conjecture of new therapeutic strategies based
on iron chelators or other iron-toxicity counteracting drugs as
a valuable approach for AD treatment (Liu et al., 2018; Ashraf
and So, 2020). Several studies supported the notion that brain
iron elevation (Lane et al., 2018; Ayton et al., 2019) or even
the levels of iron-related proteins, e.g., plasma transferrin, are
associated with AD and cognitive decline (Hare et al., 2015;
Guan et al., 2020). Furthermore, the concentration of several
elements included iron in biological fluids (Duce and Bush,
2010; Schrag et al., 2011; Cicero et al., 2017) has been evaluated
with different techniques but highlighting difficulties to compare
results. However, a direct evaluation of iron concentration in the
brain remains a difficult task and conclusive results about the
combined role of iron and iron-protein levels on biological fluids
(i.e., CSF and serum) with the preclinical stage of dementia are
not still clearly established.
Recently, the application of machine learning techniques gave
strong support to AD diagnosis, in particular for classification
tasks (Tanveer et al., 2020) and clustering analysis (Alashwal
et al., 2019), aiming at identifying which features are involved in
the conversion from early-stage AD to dementia. In particular,
clustering analysis is a potentially strategic tool able to establish
subsets of individuals sharing similar patterns and has been
applied to investigate disease-related profiles of different AD and
dementia stages (Racine et al., 2016; Alashwal et al., 2019).
This study aimed to investigate potential patterns of iron
imbalances both in CSF and in serum, to improve early diagnosis
and the related therapeutic possibility. While the content of
iron in serum was assessed using standard clinical methods to
detect transferrin (s-Tf), an accurate quantification of total iron
in CSF was obtained using atomic absorption spectrometry, not
currently used in clinical practice, leading to a potential added
value to the clinical information about the status of the patients.
Firstly, to discriminate iron profiles between different forms
of dementia, iron concentration in CSF of AD patients was
compared with patients affected by Frontotemporal Dementia
(FTD), a heterogeneous disorder with distinct pathological
features and clinical phenotypes, encompassing changes in
behavior, language, executive control, and oftenmotor symptoms
(Olney et al., 2017). Secondly, we compared patients affected
by AD, MCI, and non-demented controls, to evaluate shared
patterns and the ability to discriminate these conditions.
To check whether the new iron-related biomarkers could
add significant improvements to AD early diagnosis, a step-
by-step procedure was adopted, iteratively adding to the well-
consolidated features (Aβ42, p-Tau, and t-Tau) also the results
from s-Tf and iron content in CSF.
Cluster analysis was performed, to unravel subgroups within
heterogeneous data such that individual clusters classify similar
profiles, having better homogeneity than the whole. In particular,
the hierarchical agglomerative clustering (HAC) algorithm was
applied, a suitable technique for partitioning patients based on
their similarity.
Since clustering analysis can reveal similar (pathological)
profiles and identify potential altered biological mechanisms, we
investigated how such clusters are influenced by the addition
of the iron-related parameters and whether MCI can be
better discriminated from controls and AD. Multiclassification
algorithms with different features sets are used to compare
diagnostic power and to rank the relevance of features for the
prediction of the model.
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10/4 8/9 7/9 10/12 NS
Age at the time of CSF collection
(yrs) (mean ± SD)









Age onset (mean ± SD) (68.64 ± 7.16) (66.82 ± 6.57) (65.87 ± 7.20) (65.91 ± 8.11) NS
Aβ42 CSF (pg/mL) (mean ± SD) (917.93 ± 277.15) (832.65 ± 399.16) (432.00 ± 200.68) (819.45 ±322.91) AD < CT: (p < 0.001) †,
AD < MCI: (p=0.002) †,
AD < FTD: (p < 0.001) †
p-Tau CSF (pg/mL) (mean ± SD) (19.9 ± 8.91) (57.47 ± 58.14) (84.65 ± 45.18) (41.12 ± 23.92) AD > CT: (p < 0.001) †,
AD > FTD: (p = 0.04) †
t-Tau CSF (pg/mL) (mean ± SD) (102.76 ± 72.24) (326.18 ± 363.71) (465.81 ± 329.45) (154.53 ± 102.28) AD > CT (p=0.002) †,


















s-Tf (mg/dL) (mean ± SD) (231.44 ± 38.01) (230.78 ± 34.22) (235.55 ± 17.99) (255.72 ± 57.11) NS
AD, Alzheimer’s disease; Aβ42, forty-two amino acid-long amyloid-β peptide; CSF, cerebrospinal fluid; CT, neurological control; F, female; FTD, Frontotemporal dementia; M, male; MCI,
mild cognitive impairment; MMSE, Mini-Mental State Examination; NS, Not significant; p-Tau, hyperphosphorylated tau; s-Tf, serum transferrin; t-Tau, total tau.
†
Kruskal-Wallis test and
Dunn’s post-hoc test (Bonferroni correction for p-value).
MATERIALS AND METHODS
Participants
We retrospectively included 69 patients (35males and 34 females,
mean age: 70.5 years ± SD: 7.2), evaluated and followed at the
Department of Neurosciences of University Hospital “Città della
Salute e della Scienza,” Torino and at Fondazione IRCCS Istituto
Neurologico Carlo Besta, Milano, Italy.
CSF samples from all 69 patients, including 14 non-demented
neurological control (CT) patients, 17 patients affected by MCI,
16 AD, and 22 FTD (behavioral variant) were collected.
Diagnosis of FTD was made according to Rascovsky Criteria
(Rascovsky et al., 2011).
Diagnosis of AD has been made according to NIA-AA
(National Institute of Aging—Alzheimer Association) criteria
(McKhann et al., 2011).
For the classification of MCI, the Petersen criteria were used:
cognitive complaint, decline or impairment; objective evidence of
impairment in cognitive domains; essentially normal functional
activities; not demented (Petersen, 2004; Petersen et al., 2009).
MCI group included a mix of amnestic, non-amnestic, and
multidomain subjects, with disease onset before (N = 3) and
after (N= 13) 65 years.
As control group, CSF of 14 patients with neurological
conditions (see Supplementary Material) without dementia
was analyzed.
Cognitive functions were assessed by Mini Mental State
Examination (MMSE).
A complete description of data is available in Table 1. The
experiments conformed to the principles of the Declaration
of Helsinki and were approved by the local ethics committee.
Informed consent for liquor collection and storage relative
to the retrospective study was given by all subjects or by
their caregivers.
Details of procedure for the collection of CSF and serum
samples, also with determination of CSF levels of Aβ42, p-
Tau, and t-Tau and of serum transferrin, are reported in
Supplementary Material.
Iron Determination in CSF by GF-AAS
Frozen aliquots of CSF samples were transported on dry ice until
the shipment to the analytical chemistry laboratory, were kept
frozen during storage and unfrozen 1 h before the analysis.
The determination of iron in CSF samples was carried out
by means of Graphite Furnace Atomic Absorption Spectrometer
(GF-AAS) as detailed in Supplementary Material.
Statistical and Machine Learning Analysis
The assumption of equality of variance and normal distribution
were assessed through Levene’s test and Shapiro-Wilk’s test,
respectively. One-way analysis of variance (ANOVA) for
normally distributed variables, Kruskal-Wallis test for variables
not following a normal distribution, and chi-squared test
(for categorical variables) were conducted to determine group
differences. Post-hoc tests (t-test and Dunn’s test adjusted for
multiple comparisons errors according to Bonferroni) were
performed, respectively, after significant results of ANOVA
and Kruskal-Wallis test. The same procedures were applied to
compare clusters in the cluster analysis, described below.
Bivariate correlations between clinical data, biomarkers, and
the iron concentration levels were tested both using Spearman’s
test and Pearson’s test for non-parametric and parametric
relationships (rs = Spearman’s rank correlation coefficient, r =
Pearson’s correlation coefficient), respectively. We assumed as
Frontiers in Aging Neuroscience | www.frontiersin.org 3 February 2021 | Volume 13 | Article 607858
Ficiarà et al. Machine Learning and Alzheimer’s Disease
correlated only the variables simultaneously satisfying the two
correlation criteria, with both |r| and |rs|>0.5. Results from
statistical analysis were evaluated against a threshold of p < 0.05.
Before the cluster analysis, Hopkins’s test was applied
to assess the clustering tendency of the datasets. For the
hierarchical clustering, the clustering variables were selected
based on the results of bivariate correlations, avoiding to include
features with a high degree of collinearity (a threshold of
r > 0.7 was set Dormann et al., 2013). For the variables
presenting some association with age, additional analysis was
performed including the age correction in the clustering analysis
(Supplementary Material).
HAC was applied, a bottom-up approach in which each data
point starts in a separate cluster, and pairs of clusters are merged
at the bottom going up the hierarchy. After data standardization
(Z-score unit), patients were grouped using HAC with Ward’s
method of minimum variance and Euclidean distance metric and
visualized in dendrograms. Ward’s method joins two clusters to
make the smallest increases in the pooled within-cluster variation
(Ward, 1963).
The number of resulting clusters was set finding clustering
step where the acceleration of distance growth is the largest,
stopping the process and selecting a distance cut-off in the
dendrogram to determine the correct number of clusters
(>2 clusters). Different sets of features in two datasets were
considered for clustering, and a heatmap was used to visualize
the median value of the features in each cluster. The values of
features within each cluster are reported for the different feature
sets used (Supplementary Material).
The clusters obtained for each feature set were compared
based on the following clustering scores: Adjusted Rand Index
(ARI) and Adjusted Mutual Information (AMI), measuring the
similarity and agreement of the two assignments; V-measure,
evaluating the homogeneity, and completeness of the clusters. In
the subpopulation in which all features considered are available,
the ratio (Fe CSF/s-Tf) was calculated for each cluster and the
dataset was divided into quartiles to observe where the values of
variables in each cluster fall with respect to the whole population
(Supplementary Material).
The dataset was used to train two machine learning
models based on Support Vector Machine (SVM) and Logistic
Regression (LR) adapted for multiclass classification, using two
different sets of features, comparing the performance of the
classifiers and ranking the relevance of features. The SVM
algorithm is very popular for discrimination tasks because
it is able to reach good generalization ability and accurately
combines features, finding the maximal margin hyperplane, and
minimizing the classification error to divide data belonging to
different classes (Cortes and Vapnik, 1995).
Two feature sets used for the cluster analysis have been
included in the model. After standardization of the datasets, an
exhaustive search over parameter values for the estimators has
been carried out by cross-validated grid search to optimally tune
parameters of the classifiers.
For the present study, the OnevsRest (OVR) classifiers
based on SVM with linear kernel and LR were used for the
classification of the three groups (CT, AD, MCI) and to evaluate
the importance assigned to the features. The classification
performance of the constructed models, varying the input
features presented to it, was computed using the macro-averaged
Area Under the Receiving Operating Curve (AUROC). The
performance of the classifiers was assessed via 100 times stratified
shuffle split cross-validation method (proportion of train:test
size = 60:40). This cross-validation method returns stratified
randomized folds that preserve the percentage of samples for
each class.
The values of the importance for each feature were obtained
applying the model inspection technique based on repeated
permutations of features on test datasets. The permutation
feature importance is defined to be the change in a model score
when a single feature value is randomly shuffled. This procedure
indicates how much the model depends on the feature, breaking
the relationship between the feature and the target, correcting
possible bias of the model.
Statistical and machine learning analysis was carried out
under the programming language Python, also using library
Scikit-Learn (Pedregosa et al., 2011).
RESULTS
Demographic and Clinical Data
Demographic and clinical data of the patients classified by clinical
diagnosis as described in section Materials and Methods 2.1 are
reported in Table 1 (see also Supplementary Figure 1). Values
of MMSE and s-Tf are available for different subgroups of the
population composed of 69 patients.
In addition, the four groups were not significantly different for
values of glucose and protein dosed in CSF (data not shown) and
there were not significant differences in iron variables (s-Tf and
iron in CSF) between men and women.
The variables p-Tau and t-Tau showed a strong positive
correlation both for the whole population (rs = 0.67, r = 0.87,
p < 0.001) and for the population including only AD, MCI,
and CT patients (rs = 0.76, r = 0.92, p < 0.001). P-Tau and t-
Tau indicated positive correlations also considering AD (rs =
0.81, r = 0.88, p < 0.001), MCI (rs = 0.61, p = 0.01, r =
0.91, p < 0.001), and CT (rs = 0.73, p = 0.003, r = 0.66, p =
0.002) groups. Considering the subpopulation (s-Tf available) the
strong correlation between p-Tau and t-Tau was confirmed (rs =
0.89, r = 0.92, p < 0.001). In AD group s-Tf resulted negatively
correlated with t-Tau (rs =−0.70, p= 0.03, r=−0.67, p= 0.02).
Additional results are reported in Supplementary Material.
Iron Concentration in CSF
Total iron concentration in CSF samples of patients is shown
in Figure 1. Significant differences have been reported between
AD and all the other groups, but not between CT and MCI. No
difference was found between FTD and CT groups.
Clustering Analysis
Clustering analysis was performed including CT, MCI and AD
groups on two different populations: total dataset comprising 47
patients, and the subset composed of 29 patients for which the
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FIGURE 1 | Distribution of iron concentration in CSF samples of AD (56.3 ±
15.6 µg/L), MCI (38.6 ± 21.2 µg/L), CT (26.5 ± 9.9 µg/L), and FTD (35.2 ±
16.8 µg/L) patients by means of GF-AAS. Iron levels were significantly different
between AD and CT (p < 0.001), AD and FTD (p = 0.003), and AD and MCI (p
= 0.02). Statistical differences have been evaluated by means of
Kruskal-Wallis test and Dunn’s post-hoc test using Bonferroni correction for
p-value (*p < 0.05; **p < 0.01; ***p < 0.001).
measurement of s-Tf is available. The sets of features used to
compare the results are the following:
a Standard Biomarkers dosed in CSF (SBs) (p-Tau, Aβ42);
b SBs+ Iron in CSF
c SBs+ s-Tf
d SBs+ s-Tf+ Iron in CSF
For the application of hierarchical clustering we dropped t-Tau,
due to its high correlation with p-Tau.
SBs
HAC based on standard biomarkers (p-Tau, Aβ42) (Figure 2)
showed the emergence of three clusters (sizes: N = 10, N = 12,
N = 25). Differences in Aβ42 was very significant (p < 0.001)
between clusters 1 and 2 and cluster 2 and 3, while differences
in p-Tau concentration (p < 0.001) between clusters 1 and 2 and
clusters 1 and 3. Values of MMSE have been calculated for each
cluster [cluster 1 = (20.9 ± 6.3); cluster 2 = (25.1 ± 4.9); cluster
3 = (24.1 ± 5.4)]. External scores have been evaluated for the
clustering: V-measure (0.22), ARI (0.09), AMI (0.18).
SBs + Iron in CSF
The addition of iron dosage in CSF unraveled four clusters (sizes:
N = 9, N = 19, N = 7, N = 12) after the application of HAC,
reported in Figure 3. The clusters composed of AD and MCI
patients (cluster 3 and cluster 4) significantly differed among
them for iron (p= 0.038) and p-Tau (p< 0.001) profiles and from
cluster 2 (mainly composed of CT patients) for all variables with
high significance (p < 0.001), except for p-Tau between cluster 2
and 4 (p = 0.018). Cluster 3 differed from cluster 1 for CSF iron
content (p= 0.006).
Values of MMSE have been calculated for each cluster [cluster
1= (24.7± 4.8); cluster 2= (25.2± 4.5); cluster 3= (22.1± 4.7);
cluster 4= (21.6± 7.3)].
The addition of CSF iron improved V-measure (0.25), ARI
(0.16), and AMI (0.20) with respect to the same scores obtained
with the biomarkers set, described in the previous section.
SBs + s-Tf
Considering the subpopulation including data of s-Tf (N =
29 patients), the results for HAC using same feature sets
as in sections SBs and SBs + Iron in CSF are reported
in Supplementary Figures 2, 3. In this subpopulation, the
application of HAC using the feature set comprising biomarkers
and s-Tf revealed four clusters (sizes: N = 7, N = 6, N = 9, N
= 7), reported in Figure 4. Significant differences among clusters
were found for all the features values between cluster 1 and 2 (for
Aβ42, p-Tau p < 0.001; for s-Tf p = 0.02), for the p-Tau values
(p < 0.001) when comparing clusters 1 and 3 and 1 and 4; s-Tf
differed between clusters 2 and 4 (p = 0.001) and 3 and 4 (p <
0.001); Aβ42 was significantly different when comparing clusters
2 and 3 (p < 0.001) while the difference in Aβ42 between clusters
3 and 4 is borderline (p= 0.05).
Values of MMSE have been calculated for each cluster [cluster
1= (22.6± 4.8); cluster 2= (21.1± 3.6); cluster 3= (21.5± 6.9);
cluster 4= (27.5± 2.8)].
In this case, clustering scores showed the following values:
V-measure (0.32), ARI (0.18), AMI (0.25).
SBs + s-Tf + Iron in CSF
Considering all the above features four clusters emerged (sizes:
N = 7, N = 7, N = 8, N = 7). The application of HAC in the
subpopulation for which s-Tf is available (Figure 5) reported an
increase of clustering scores (V-measure = 0.43; ARI = 0.28;
AMI = 0.37). Cluster 1 and cluster 2 are composed only by AD
and MCI patients. One of these clusters (cluster 1) presented
significant difference in the levels of s-Tf (p= 0.002), Iron CSF (p
= 0.004), and p-Tau (p= 0.007) with respect to cluster 3 (mainly
CT patients). Cluster 2 differed from cluster 4 (composed only by
MCI and CT patients) in the biomarkers (for Aβ42 p= 0.004; for
p-Tau p < 0.001) and s-Tf (p = 0.008) profiles. Clusters 1 and 2,
as well as clusters 2 and 3, significantly differed only for p-Tau (p
< 0.001). Finally, cluster 4 differed from cluster 3 only for the s-Tf
values (p <0.001).
Values of MMSE for each cluster were: [cluster 1= (20.6
± 6.9); cluster 2= (22.6 ± 4.8); cluster 3= (27.6 ± 2.5);
cluster 4= (21.1± 3.6)].
The (Fe CSF/s-Tf) ratio in cluster 3 (0.15) and cluster 4
(0.11) is lower with respect to cluster 1 (0.23) and cluster 2
(0.24), in which the ratio is increased. Considering the relevant
subpopulation, the (Fe CSF/s-Tf) ratio showed highest values for
AD (0.24 ± 0.07), followed by MCI (0.18 ± 0.09) and finally
CT group (0.13± 0.06), reporting a significant difference between
AD and CT (p < 0.01).
We performed additional HAC analysis considering age
correction for the variable s-Tf, showing a sharper separation on
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FIGURE 2 | Results of hierarchical clustering using standard biomarkers Aβ42 and p-Tau, dosed in CSF. Left: Dendrogram (yellow = MCI; red = AD; green = CT) and
distribution of patients within the three clusters. Right: Heatmap using the median value of the features (Z-score unit) in each cluster. AD, Alzheimer’s Disease; CT,
neurological control; MCI, Mild Cognitive Impairment.
FIGURE 3 | Results of hierarchical clustering using biomarkers and iron concentration in CSF. Left: Dendrogram (yellow = MCI; red = AD; green = CT) and
distribution of patients within the four clusters. Right: Heatmap using the median value of the features (Z-score unit) in each cluster. AD, Alzheimer’s Disease; CT,
neurological control; MCI, Mild Cognitive Impairment.
s-Tf profiles albeit without substantial differences in the cluster
composition (Supplementary Figures 4–6).
Classification Models
We finally used a Linear SVM and LR model to evaluate the
classification performance based on the same feature sets used for
the clustering analysis in the population (N = 47). For SVM, the
classification performance (AUROC) using SBs (Aβ42, p-Tau)
and SBs + Iron in CSF was (0.74 ± 0.14) and (0.73 ± 0.12),
respectively. In the first case, the values of feature importance
for the biomarkers set showed a higher weight for Aβ42 (0.21
± 0.18) respect to p-Tau (0.15 ± 0.11). In the second case, CSF
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FIGURE 4 | Results of hierarchical clustering using biomarkers and s-Tf. Left: Dendrogram (yellow = MCI; red = AD; green = CT) and distribution of patients within
the four clusters. Right: Heatmap using the median value of the features (Z-score unit) in each cluster. AD, Alzheimer’s Disease; CT, neurological control; MCI, Mild
Cognitive Impairment.
FIGURE 5 | Results of hierarchical clustering using biomarkers, s-Tf and CSF iron. Left: Dendrogram (yellow = MCI; red = AD; green = CT) and distribution of
patients within the four clusters. Right: Heatmap using the median value of the features (Z-score unit) in each cluster. AD, Alzheimer’s Disease; CT, neurological
control; MCI, Mild Cognitive Impairment.
iron reported a higher value (0.07 ± 0.09) respect to p-Tau (0.06
± 0.09) and Aβ42 (0.03 ± 0.12). For LR model, AUROC using
SBs and SBs + Iron in CSF was (0.77 ± 0.12) and (0.75 ± 0.12),
respectively. The values of feature importance for the biomarkers
set showed a higher weight for Aβ42 (0.20 ± 0.14) respect to p-
Tau (0.11± 0.13). Even in LR model, CSF iron reported a higher
value (0.10± 0.02) respect to p-Tau (0.06± 0.13) and Aβ42 (0.09
± 0.08). In our dataset, for both models the addition of age as
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feature did not improve the AUROC, and the value of feature
importance for age was not relevant (around zero).
DISCUSSION
The present results support the hypothesis that iron
accumulation is involved in AD neurodegeneration. In clinical
practice, the pathological changes occurring in AD can be
detected by the use of biomarkers in different modalities, among
which the evaluation on CSF (i.e., Tau and Aβ biomarkers)
is less accessible but presents lower intrinsic protease activity
than blood and reflects brain changes, helping to diagnose
AD pathology in both the prodromal and the dementia stages
(Lashley et al., 2018).
In our study, both the “standard” biomarkers significantly
differed between AD and CT groups (only CSF Aβ42 between
AD and MCI), but this result requires confirmation in a
larger cohort of patients also due to the large dispersion of
biomarker values in our MCI population (Table 1). In fact, core-
AD hallmarks are present also in elder healthy people with
good cognitive function (Driscoll and Troncoso, 2011), probably
showing different patterns only with respect to the AD brain.
We added the information on iron content in CSF, intending to
discover shared profiles and potentially improve early diagnosis.
The analytical measurements of total iron in CSF bymeans of GF-
AAS is expected to provide an accurate quantification, reflecting
the iron status in brain patients more directly than brain imaging
techniques. Indeed, biochemical changes in the brain, occurring
in preclinical phases produce corresponding alterations in the
CSF (Jack et al., 2010). Iron concentration in CSF is minimal and
therefore very difficult to measure, requiring accurate and highly
sensitive techniques such as atomic absorption spectrometry,
providing reproducible and reliable results, without the need for
hard pre-treatment of CSF samples. Moreover, this measurement
is not currently used in clinical practice, leading an added value
for the standard information on iron status in the brain.
Several studies evaluated iron levels in biological fluids, and
meta-analysis conducted by Tao et al. showed lower iron in serum
and an iron overload in several specific brain regions of AD
patients, however highlighting the need for further studies to
evaluate iron in CSF (Tao et al., 2014).
In the present work, CSF iron concentration in 69 patients
was analyzed, finding a statistically significant increase in the
total iron concentration in AD with respect to CT patients,
and between AD and MCI (Figure 1), showing a potential
discriminating power of our analysis. Iron dysregulation could
generate a progressively toxic environment during the different
stages of dementia. In fact, a well-known consequence of
increased iron concentration is the production of ROS, leading to
DNA damage and cell death (Zecca et al., 2004), that feature AD.
The concentration of iron in CSF is very low, and it has been
suggested that Tf saturation in the CSF is much higher than in
the periphery and that a larger proportion of free iron circulates
the CNS (Leitner and Connor, 2012). An imbalance of free
iron can be responsible for toxic damage taking part in Fenton
reaction and consequently to the onset of neurodegeneration.
Interestingly, it is reported that different stages of cognitive
and functional impairment are associated with changes in CSF
reactive iron, possibly in relation to the development of cognitive
and functional decline (Lavados et al., 2008).
The importance of iron in AD and aging has been shown also
from the evaluation of altered local levels of proteins regulating
iron levels, such as transferrin (Loeffler et al., 1995; Lu et al.,
2018).
Then, it has been assessed that CSF ferritin, the iron storage
protein of the body, plays a role in AD. It has been demonstrated
that CSF ferritin, assumed to be an index of brain iron load,
is strongly associated with CSF apolipoprotein E levels and
was elevated by the Alzheimer’s risk allele, APOE-ε4 (Ayton
et al., 2015). Also, CSF ferritin levels have been associated
with longitudinal changes in CSF Aβ and Tau, showing that
iron might facilitate Aβ deposition in AD and accelerate the
disease process (Ayton et al., 2018). These evidences provide
proofs that a disturbance in iron metabolism can be involved in
neurodegenerative processes.
To check whether our technique was accurate enough to
detect small differences in the iron concentration in CSF and to
evaluate the possibility to discriminate between AD and other
dementias, in the first part of our study we compared AD and
FTD patients. The results (Figure 1) showed a marked difference
in iron concentrations in FTD patients with respect to AD,
suggesting a possible different role for this metal in these two
types of dementia. This result should be confirmed in larger
cohorts, however, different levels of biological metals in CSF have
been showed in different neurodegenerative diseases (Hozumi
et al., 2011), in particular AD, Amyotrophic Lateral Sclerosis, and
Parkinson disease, so it is plausible that a difference exists also in
FTD (Ashraf and So, 2020).
AD is a complex disease (Devi and Scheltens, 2018),
requiring advanced computational algorithms to discover deep
relationships in the data and their relative patterns. In this
work we applied clustering analysis, a powerful technique
suitable to discover patterns and similar subgroups, which has
been successfully applied in recent studies on AD (Racine
et al., 2016; Alashwal et al., 2019; Toschi et al., 2019). We
tested how considering different sets of features can better
diagnose the progression of AD and point out new potential
pathological mechanisms involved in neurodegeneration. Results
from hierarchical clustering analysis revealed that using the
standard AD biomarkers Aβ42 and p-Tau, two groups of patients
presented alternative signatures (clusters 1 and 2, Figure 2).
One of these (cluster 1, Figure 2) could be associated with
the AD profile showing low levels of Aβ42 and high levels
of p-Tau, reflecting the accumulation of amyloid plaques and
neurofibrillary tangles. However, a third subgroup emerged
(cluster 3, Figure 2) with a heterogeneous composition of AD,
MCI, and CT, underlining that the two standard biomarkers
alone are unable of a sharp discrimination of the patient
status. Probably, the sparse presence of MCI patients in
all the clusters is due to the wide spectrum of cognitive
and functional impairment that is captured by the MCI
designation, impacting the heterogeneity of outcomes (Roberts
and Knopman, 2013).
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Interestingly, the information on iron concentration in CSF
added one more cluster, generating two separated groups
composed of patients classified with diagnosis of AD and MCI
(clusters 3 and 4, Figure 3), both presenting low values of MMSE.
These clusters differed for p-Tau and CSF iron levels, albeit
presenting similar Aβ42 profile. Cluster 3 could be considered
as a typical AD profile, with low levels of Aβ42 and high values
for p-Tau, and in addition higher values of iron with respect
to the two clusters containing mainly CT patients (clusters 1
and 2, Figure 3). Cluster 4 presents low levels of Aβ42, lower
levels of p-Tau with respect to cluster 3, and the highest levels of
CSF iron. The improvement of clustering scores assessed a better
discrimination of patients by adding the iron content in CSF to
the standard biomarkers. One possible interpretation of these
results is that cluster 4 could be associated to patients in stages
of dementia in which p-Tau starts to aggregate but deposition of
Aβ plaques is already present.
In fact, according to the current models describing the timing
of pathophysiological brain events in relation to the clinical
course, preclinical phases of AD are characterized by plaques
deposition, followed by later spread of neurofibrillary tangles
(Jack et al., 2010; Long and Holtzman, 2019). Furthermore,
the higher iron concentration combined with lower levels of
p-Tau could suggest a harmful interaction between iron and
p-Tau accumulation at early stages, inducing or worsening
neurodegenerative events. This hypothesis is consistent with
several studies, supporting the evidence that iron can promote
the aggregation and pathogenicity of Tau (Smith et al., 1997;
Yamamoto et al., 2002; Lovell et al., 2004; Ahmadi et al.,
2017; Spotorno et al., 2020). Chelation therapies, based on
intranasal deferoxamine treatment, may exert suppressive effects
on the iron-induced tau phosphorylation, providing a valuable
approach in preventing AD progression (Guo et al., 2013). In
addition, further studies on patients reported an investigation
of novel treatment strategy based on a metal-protein-attenuating
compound to reduce toxic properties of Aβ mediated by copper
and zinc (Ritchie et al., 2003; Lannfelt et al., 2008).
According to our results, the clusters containing patients
affected by AD showed an increased level of iron with low
levels of Aβ42, hallmark for senile plaques deposition, which
confirms the link between iron and Aβ plaques. There are
evidences for a variety of interactions between iron and Aβ: iron
accumulates and co-localizes with Aβ plaques (Connor et al.,
1992; Meadowcroft et al., 2009; Ndayisaba et al., 2019), their
binding can form redox reactive and toxic species (Nakamura
et al., 2007; Bousejra-ElGarah et al., 2011), with evidence for
the formation of an iron-amyloid complex (Telling et al., 2017),
and also iron levels can increase prior to plaques formation
in an animal model of AD (Leskovjan et al., 2011). Increased
iron levels are believed to enhance Aβ production via the
downregulation of furin (Silvestri and Camaschella, 2008) and
the iron regulatory pathways are also involved in proteostasis
of Amyloid Precursor Protein (APP) (Rogers et al., 2008; Duce
et al., 2010). It has been hypothesized that brain oxidative damage
concurs to AD pathogenesis before Aβ accumulation (Praticò
et al., 2001), therefore iron accumulation might precede and
cause the formation of plaques. Recently it has been proposed
that an increase in the intracellular labile iron levels, due to
mitochondria dysfunction, enhances the rate of APP synthesis
and the activity of APP cleavage by beta-secretase resulting
in Aβ formation (Kozlov et al., 2017). In addition, a recent
study confirmed the link between iron retention in cells and
mislocalization of APP, due to alteration of ferroportin activity
in the modulation of iron efflux: this effect causes a change in
endocytic trafficking with consequent neuronal iron elevation
and oxidative damage that feature AD pathology (Tsatsanis et al.,
2020).
Further connections between iron and lipoprotein
metabolism have been detected, highlighting causative
interaction and synergies between genes of iron homeostasis and
established genetic risk factors of AD, such as APOE4, suggesting
the iron metabolism as a possible therapeutic target (Tisato et al.,
2018).
Emerging evidence suggested that blood iron homeostasis is
altered in AD and already in MCI (Faux et al., 2014; Ashraf
et al., 2020; Guan et al., 2020), including systemic variation
of markers of iron metabolism, such as transferrin saturation
and ceruloplasmin/transferrin ratio in serum (Squitti et al.,
2010). Interestingly, in our case, we found a negative correlation
between t-Tau and Tf in serum in AD that can support a role of Tf
in neurodegeneration. Despite our observations require further
confirmation in a larger cohort of patients, cluster analysis also
found different concentrations of Tf in serum and iron levels in
CSF for patients with MCI and dementia.
Using features set including standard biomarkers and s-Tf,
four clusters emerged, with different profiles of s-Tf. Cluster
1 (Figure 4) containing mainly AD patients, associated typical
AD profile with a lower level of s-Tf compared to two of three
remaining clusters. This result might support that serum iron
is lower in AD than in healthy controls (Tao et al., 2014), and
that decreased plasmatic iron in AD could be due to transferrin
desaturation (Hare et al., 2015), pointing out a role for systemic
variations of iron metabolism in neurodegeneration. However,
the other cluster comprising AD and MCI patients (cluster
3, Figure 4) reported a higher level of s-Tf with respect to
the cluster 4 (Figure 4) composed of MCI and CT patients,
requiring a further investigation on the s-Tf profiles in a larger
population. Using a step-by-step approach, we finally used
the full set of features, including also information on iron
concentration in CSF, which largely improved the discrimination
of patients according to their clinical diagnosis. Clustering
analysis unraveled four clusters, visualized in the dendrogram
(Figure 5), in which AD and CT patients are well-separated,
supported by a good improvement of clustering scores. As
previously discussed, the presence of MCI patients in all clusters
reflected their wide spectrum in the current MCI diagnosis.
Interestingly, a recent study reported that postmortem MRI and
histology demonstrated differential iron accumulation in early-
and late-onset AD (Bulk et al., 2018), showing the presence of
various distribution patterns for iron accumulation in subtypes
of AD patients.
Two subgroups containing AD and MCI patients (clusters 1
and 2, Figure 5) differed in p-Tau levels and showed CSF iron
levels higher with respect to the clusters composed of CT and
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MCI (clusters 3 and 4, Figure 5). This result sustains our previous
hypothesis that iron concentration and p-Tau levels in CSF could
play a crucial role in differentiating the actual stage of dementia.
The interpretation of clusters 3 and 4 (Figure 5) is less simple.
The different profiles of s-Tf for these clusters, containing CT
and MCI patients, could be due both to the small size of samples
requiring further investigation in a larger cohort.
Significant differences in s-Tf profiles have been detected in
the clusters containing mainly AD and CT, respectively, showing
also an increased ratio between the iron content in CSF and s-Tf
in clusters only formed by patients affected by dementia and for
the AD with respect to CT group. It is increasingly recognized
that AD is a clinically heterogeneous disease withmultiple causes,
with an important role for brain vasculature (Montagne et al.,
2017; Sweeney et al., 2018a). Our approach could be considered
an indirect evaluation of the potential connection between iron
homeostasis and blood-brain barrier (BBB) dysfunction. BBB
dysfunction is a mechanism involved in the neurodegeneration
and subsequently in cognitive impairment (Nation et al., 2019),
and recently included in a hypothetical model of AD biomarkers
(Sweeney et al., 2018b). Interestingly, the export mechanisms
at the BBB level are altered in dementia, leading to potential
targets for treatment (Pahnke et al., 2014). AD is characterized by
altered BBB permeability and a link between iron-overload and
BBB breakdown and brain mitochondrial dysfunction has been
demonstrated (Sripetchwandee et al., 2016).
In fact, BBB prevents the diffusion of Tf from blood into
CNS, as well as the migration of non-transferrin bound iron
(NTBI), potentially toxic from the brain. Tf is transported
across brain capillary endothelial cells following an endocytic
mechanism mediated by Tf-receptors (Moos et al., 2007). The
breakdown or alteration of this system could be part of the
cause for pathological accumulation of iron into the brain and
consequently in the CSF. In fact, CSF can be produced both via
the choroid plexus or by the interstitial fluid of the brain (Nakada
and Kwee, 2019).
Moreover, various studies proposed that iron trafficking across
the blood-brain capillaries is involved in the aggregation of
Aβ peptides leading to the potential onset of AD (McCarthy
and Kosman, 2015), and also that iron accumulation may be
associated with the age-induced changes in the expression of iron
metabolism proteins in the brain (Lu et al., 2017).
To extract further information on the data, useful for
future clinical studies, machine learning models have been
trained to evaluate the impact of the inclusion of iron-related
data in the diagnostic power of dementia. We selected LR
model and linear SVM, one of the most used techniques for
AD classification problem (Tanveer et al., 2020), giving good
generalization performances also for small samples. In particular,
the present results for both models were comparable, underlining
a potential relevance of the iron-related feature (CSF iron) for
the classification of AD, CT, MCI patients. Although AUROC
did not detect a significant increase, in ranking the relevance
of features the addition of CSF iron could suggest a potential
role in the improvement of the diagnostic power of AD, MCI,
and CT patients, provided further investigation on larger samples
are performed. Moreover, the cross-sectional nature of our study
is a limitation of the present investigation and longitudinal
studies will be necessary to clarify the involvement of abnormal
iron homeostasis in different stages of the disease process, i.e.,
including iron-related data from blood or MRI. Additionally,
further studies with larger samples will be useful to quantitatively
parse out our results and to confirm the stratification of patients
turned out in the cluster analysis.
Finally, the use of cluster analysis proved its potential utility
for identifying patterns of variables that might characterize
disease progression. The addition of iron-related data to the core-
biomarkers can help to capture the multifaceted nature of AD,
co-characterized by Aβ plaques deposition and neurofibrillary
tangles aggregation as well as other related processes. Future
works should focus on the evaluation of abnormal iron
concentrations in different stages of dementia, which can
generate deposition in CSF or changes in circulating iron
(protein-bound or free) arising from possible imbalances of the
blood-brain exchange of iron. The evaluation of iron in the CSF
can improve the tuning of personalized therapeutic strategies
based on systemic or intrathecal administration of chelating
agents acting directly into the brain.
In conclusion, our results support the evidence of iron
overload in AD, and consequently the hypothesis that different
clinical conditions with specific backgrounds involve the
actual iron brain levels. Cluster analysis revealed a new
potential stratification of patients when new parameters,
related to the iron concentration in serum and CSF, are
accounted for, advancing our understanding of the role of iron
dysregulation in AD pathophysiology. Tight regulation of iron
metabolism is pivotal to warrant neuronal homeostasis and its
investigation can prompt avenues for both research on new
pathological mechanisms involved in neurodegeneration and
development of new treatments. The potential addition
of iron-related data in clinical evaluation of dementia
could improve the early diagnostic power and support new
personalized disease-modifying therapies based on iron
chelation able to slow the progression and worsening of the
neurodegenerative processes.
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